Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has received a consensus rating of “Moderate Buy” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation […]
More Stories
Locus Chain Trading 7% Lower This Week (LOCUS)
Locus Chain (LOCUS) traded 0.1% lower against the US dollar during the 1 day period ending at 17:00 PM E.T....
GateToken (GT) Price Reaches $8.53 on Top Exchanges
GateToken (GT) traded 1.5% higher against the dollar during the 24-hour period ending at 17:00 PM E.T. on November 5th....
Jack Henry & Associates (NASDAQ:JKHY) Releases FY 2025 Earnings Guidance
Jack Henry & Associates (NASDAQ:JKHY – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday...
SGL Carbon (ETR:SGL) Reaches New 52-Week Low – Here’s Why
SGL Carbon SE (ETR:SGL – Get Free Report) reached a new 52-week low on Tuesday . The company traded as...
Costco Wholesale (NASDAQ:COST) Stock Price Up 0.8% – Still a Buy?
Shares of Costco Wholesale Co. (NASDAQ:COST – Get Free Report) were up 0.8% during mid-day trading on Tuesday . The...
Celestia (TIA) Price Tops $4.23 on Top Exchanges
Celestia (TIA) traded up 0% against the U.S. dollar during the 1-day period ending at 18:00 PM ET on November...